PFE Pfizer Inc

By Matt Grossman

Pfizer Inc. and BioNTech SE's Covid-19 vaccine showed strong safety and efficacy in children aged 12 to 15 in a Phase 3 trial of its use among that cohort, the companies said Monday.

Data from the trial showed that the vaccine was 100% effective against Covid-19 from seven days after the second dose through more than four months after the second dose, the companies said. There were no serious safety concerns observed in people over six months of safety follow-up, Pfizer and BioNTech said.

The data will be the basis for a regulatory submission seeking full approval for the vaccine in people aged 12 to 15. The vaccine is now available to people that age in the U.S. via an emergency-use authorization from the Food and Drug Administration.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

November 22, 2021 07:14 ET (12:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.